Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Amsterdam Molecular Therapeutics (AMT) Holding N.V. Product Pipeline Review H2 2011
Market Study
Published: September 2011
Pages: 59
Tables: For full details, please email deborahf@cmsinfo.com
From: GBP 312.50 Buy Now!
Research from: Global Markets Direct
Sector: Corporate & Fiscal
Amsterdam Molecular Therapeutics (AMT) Holding N.V. Product Pipeline Review H2 2011
Summary
Global Market Direct's pharmaceuticals report, Amsterdam Molecular Therapeutics (AMT) Holding N.V. Product Pipeline Review H2 2011 provides data on the Amsterdam Molecular Therapeutics (AMT) Holding N.V.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Amsterdam Molecular Therapeutics (AMT) Holding N.V.'s corporate website, SEC filings, investor presentations and featured press releases, both from Amsterdam Molecular Therapeutics (AMT) Holding N.V. and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Brief Amsterdam Molecular Therapeutics (AMT) Holding N.V. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Amsterdam Molecular Therapeutics (AMT) Holding N.V. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Amsterdam Molecular Therapeutics (AMT) Holding N.V. with complete description of the product?s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Amsterdam Molecular Therapeutics (AMT) Holding N.V.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Amsterdam Molecular Therapeutics (AMT) Holding N.V.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Amsterdam Molecular Therapeutics (AMT) Holding N.V. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Amsterdam Molecular Therapeutics (AMT) Holding N.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Amsterdam Molecular Therapeutics (AMT) Holding N.V..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Amsterdam Molecular Therapeutics (AMT) Holding N.V. and identify potential opportunities in those areas.
Summary
Global Market Direct's pharmaceuticals report, Amsterdam Molecular Therapeutics (AMT) Holding N.V. Product Pipeline Review H2 2011 provides data on the Amsterdam Molecular Therapeutics (AMT) Holding N.V.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Amsterdam Molecular Therapeutics (AMT) Holding N.V.'s corporate website, SEC filings, investor presentations and featured press releases, both from Amsterdam Molecular Therapeutics (AMT) Holding N.V. and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Brief Amsterdam Molecular Therapeutics (AMT) Holding N.V. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Amsterdam Molecular Therapeutics (AMT) Holding N.V. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Amsterdam Molecular Therapeutics (AMT) Holding N.V. with complete description of the product?s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Amsterdam Molecular Therapeutics (AMT) Holding N.V.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Amsterdam Molecular Therapeutics (AMT) Holding N.V.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Amsterdam Molecular Therapeutics (AMT) Holding N.V. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Amsterdam Molecular Therapeutics (AMT) Holding N.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Amsterdam Molecular Therapeutics (AMT) Holding N.V..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Amsterdam Molecular Therapeutics (AMT) Holding N.V. and identify potential opportunities in those areas.